Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists

ISSN： 0925-5710

Source： International Journal of Hematology, Vol.98, Iss.1, 2013-07, pp. : 34-47

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The biology of thrombopoietin and thrombopoietin receptor agonists

By Kuter David

International Journal of Hematology, Vol. 98, Iss. 1, 2013-07 ,pp. : 10-23

Springer Publishing Company

Access to resources Recommend Favorite

Thrombopoietin

By Bolam S.

Transfusion Science, Vol. 18, Iss. 1, 1997-03 ,pp. : 129-137

Elsevier

Access to resources Recommend Favorite

Thrombopoietin

By Bolam S.

Transfusion and Apheresis Science, Vol. 18, Iss. 1, 1997-03 ,pp. : 129-137

Elsevier

Access to resources Recommend Favorite

MplK, a natural variant of the thrombopoietin receptor with a truncated cytoplasmic domain, binds thrombopoietin but does not interfere with thrombopoietin-mediated cell growth

By Millot G.A. Feger F. Garcon L. Vainchenker W. Dumenil D. Svinarchuk F.

Experimental Hematology, Vol. 30, Iss. 2, 2002-02 ,pp. : 166-175

Elsevier

Access to resources Recommend Favorite

Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes

By Townsley Danielle Desmond Ronan Dunbar Cynthia Young Neal

International Journal of Hematology, Vol. 98, Iss. 1, 2013-07 ,pp. : 48-55

Springer Publishing Company

Access to resources Recommend Favorite